• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    4/7/25 7:40:08 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email
    8-K
    0000897448falseAMARIN CORP PLC\UK00-000000000008974482025-04-042025-04-04

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): April 4, 2025

    Amarin Corporation plc

    (Exact name of registrant as specified in its charter)

     

     

    England and Wales

    0-21392

    Not applicable

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification No.)

    One Central Plaza, 5th Floor, 36 Dame Street,

    Dublin D02 EF64, Ireland

    Not applicable

    (Address of principal executive offices)

    (Zip Code)

    Registrant’s telephone number, including area code: + 353 1 6699 020

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading
    Symbol

    Name of each exchange
    on which registered

    American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc

    AMRN

    Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On April 4, 2025, the Board of Directors (the “Board”) of Amarin Corporation plc (the “Company”) appointed Michael Torok, 46, to the Board to a term commencing on such date. In accordance with the Company’s articles of association, Mr. Torok will serve until the Company’s 2025 annual general meeting of shareholders, when he will be a nominee for election to the Board by a vote of the Company’s shareholders. Mr. Torok has not been assigned to any committees of the Board.

    Mr. Torok will receive annual compensation for his service on the Board and any applicable committees, in each case, in accordance with the Company’s non-employee director compensation policy, the material terms of which policy, currently in effect, are disclosed under “Director Compensation-Non-Employee Director Compensation” of the Company’s Definitive Proxy Statement, filed with the U.S. Securities and Exchange Commission on March 4, 2024. The Company expects to enter into a deed of indemnity with Mr. Torok, in substantially the same form entered into with the other directors of the Company.

    There are no other arrangements or understandings between Mr. Torok and any other person pursuant to which Mr. Torok was selected as a director. Mr. Torok is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    99.1

    Press release, dated April 7, 2025 (furnished herewith).

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

    * * *

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: April 7, 2025

     

    Amarin Corporation plc

     

     

     

     

    By:

    /s/ Aaron Berg

     

     

     

    Aaron Berg

    President and Chief Executive Officer

     

     


    Get the next $AMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings